Discontinued — last reported Q4 '25
Wabtec Acquisitions increased by 38.8% to $1.06B in Q1 2026 compared to the prior quarter. Over 4 years (FY 2021 to FY 2025), Acquisitions shows an upward trend with a 55.1% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.70M | $0.00 | $29.90M | $0.00 | $69.00M | $0.00 | $20.00M | $77.00M | $77.00M | $77.00M | $77.00M | $42.00M | $42.00M | $42.00M | $42.00M | $0.00 | $21.00M | $1.73B | $765.00M | $1.06B |
| QoQ Change | — | -100.0% | — | -100.0% | — | -100.0% | — | +285.0% | +0.0% | +0.0% | +0.0% | -45.5% | +0.0% | +0.0% | +0.0% | -100.0% | — | >999% | -55.9% | +38.8% |
| YoY Change | — | — | — | — | >999% | — | -33.1% | — | +11.6% | — | +285.0% | -45.5% | -45.5% | -45.5% | -45.5% | -100.0% | -50.0% | >999% | >999% | — |